Monoclonal Antibody-Based ELISA Quantification of Serum Methylglyoxal-Derived Hydroimidazolone-1
Diagnostics · 16.08.2026 · 16 (16) · 2593
DOI: 10.3390/diagnostics16162593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 16.08.2026. Verfasst von Jun Nojima und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nagahama Institute for Biochemical Science, Oriental Yeast Co., Ltd., Nagahama 174-8505, Japan. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Methylglyoxal-derived hydroimidazolone-1 (MG-H1), an advanced glycation end product, has implications in the pathogenesis of diabetic kidney disease (DKD). Although liquid chromatography–mass spectrometry is the current gold standard for quantifying MG-H1, its overall complexity limits its utility. We developed an ELISA to measure MG-H1 using a specific monoclonal antibody.
Methods
Competitive ELISA was used to quantify total, high-molecular-weight (HMW), and low-molecular-weight (LMW) MG-H1 in serum. The assay’s specificity was validated against structurally related compounds. Spike-and-recovery experiments were conducted to assess accuracy and precision. Serum samples from healthy controls, diabetic patients without kidney disease, and patients with DKD were analyzed (n = 10, 23, and 19, respectively). MG-H1’s correlation with renal biomarkers and diagnostic performance was assessed using receiver operating characteristic analyses.
Results
The ELISA exhibited preferential reactivity toward MG-H1 compared with structurally related compounds. Spike-and-recovery experiments resulted in recovery rates ranging 108–119%. MG-H1 levels were increased in patients with DKD, although the magnitude of the changes varied among the MG-H1 forms. All MG-H1 forms correlated positively with serum creatinine and blood urea nitrogen, and negatively with estimated glomerular filtration rate. No significant correlations were observed with glycoalbumin, and only a modest association was observed between LMW MG-H1 and HbA1c. Exploratory ROC analyses suggested that all MG-H1 forms could discriminate DKD from DM, with total and HMW MG-H1 showing performance comparable to that of conventional renal function markers.
Conclusions
This competitive ELISA enables high-throughput quantification of MG-H1 in serum and demonstrates analytical feasibility; further multicenter validation is required before clinical implementation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nagahama Institute for Biochemical Science, Oriental Yeast Co., Ltd., Nagahama 174-8505, Japan.
- Department of Advanced Diagnostic System Development, Fujita Health University Graduate School of Medical Sciences, Toyoake 470-1192, Japan.
Zitieren
APA
Nojima, J., Tasaka, M., Fujigaki, H., Sugiura, S., Yamamoto, Y., Enomoto, T., Matuo, Y., & Saito, K. (2026). Monoclonal Antibody-Based ELISA Quantification of Serum Methylglyoxal-Derived Hydroimidazolone-1. Diagnostics, 16(16), 2593. https://doi.org/10.3390/diagnostics16162593
Vancouver
Nojima J, Tasaka M, Fujigaki H, Sugiura S, Yamamoto Y, Enomoto T, et al. Monoclonal Antibody-Based ELISA Quantification of Serum Methylglyoxal-Derived Hydroimidazolone-1. Diagnostics. 2026;16(16):2593. doi:10.3390/diagnostics16162593
BibTeX
@article{Nojima2026,
author = {Nojima, Jun and Tasaka, Masatsuna and Fujigaki, Hidetsugu and Sugiura, Sayaka and Yamamoto, Yasuko and Enomoto, Tetsuro and Matuo, Yushi and Saito, Kuniaki},
title = {Monoclonal Antibody-Based ELISA Quantification of Serum Methylglyoxal-Derived Hydroimidazolone-1},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {16},
pages = {2593},
doi = {10.3390/diagnostics16162593}
}
EUVIMED